Several important treatments have emerged to help prevent infection from Respiratory Syncytial Virus (RSV) in those that are most susceptible to it; namely young children and adults. Specifically, the FDA recently approved Arexvy, the world’s first vaccine to fight RSV in adults aged 60 and older. According to its manufacturer GSK, the single shot provides […]
